Stifel Financial Corp Buys 224,594 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Stifel Financial Corp grew its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 103.9% in the 3rd quarter, Holdings Channel.com reports. The fund owned 440,666 shares of the company’s stock after buying an additional 224,594 shares during the period. Stifel Financial Corp’s holdings in Takeda Pharmaceutical were worth $6,266,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Millennium Management LLC boosted its holdings in Takeda Pharmaceutical by 87.1% in the second quarter. Millennium Management LLC now owns 4,346,151 shares of the company’s stock worth $56,239,000 after acquiring an additional 2,023,707 shares in the last quarter. FMR LLC boosted its holdings in Takeda Pharmaceutical by 10.9% in the third quarter. FMR LLC now owns 2,908,918 shares of the company’s stock worth $41,365,000 after acquiring an additional 286,052 shares in the last quarter. Van ECK Associates Corp boosted its holdings in Takeda Pharmaceutical by 6.6% in the third quarter. Van ECK Associates Corp now owns 2,175,236 shares of the company’s stock worth $30,149,000 after acquiring an additional 134,407 shares in the last quarter. Managed Asset Portfolios LLC boosted its holdings in Takeda Pharmaceutical by 0.3% in the third quarter. Managed Asset Portfolios LLC now owns 1,617,541 shares of the company’s stock worth $23,001,000 after acquiring an additional 4,069 shares in the last quarter. Finally, Cowen AND Company LLC acquired a new stake in Takeda Pharmaceutical in the second quarter worth about $6,866,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Trading Down 0.2 %

Shares of NYSE:TAK opened at $13.42 on Friday. Takeda Pharmaceutical Company Limited has a 52-week low of $12.57 and a 52-week high of $15.08. The stock has a market cap of $42.70 billion, a price-to-earnings ratio of 23.14, a PEG ratio of 0.26 and a beta of 0.51. The company has a quick ratio of 0.77, a current ratio of 1.28 and a debt-to-equity ratio of 0.64. The business has a 50-day moving average price of $13.81 and a 200-day moving average price of $13.87.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.